相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Michael J. Wagner et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Incidence and outcomes of cutaneous angiosarcoma: A SEER population-based study
Rosalynn R. Z. Conic et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez et al.
NATURE (2020)
The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research
Corrie A. Painter et al.
NATURE MEDICINE (2020)
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Shirish Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase 2 study of pembrolizumab in patients with advanced rare cancers
Aung Naing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma
Jason Yongsheng Chan et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
Vaia Florou et al.
Journal for ImmunoTherapy of Cancer (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Epidemiology, tumor characteristics and survival in patients with angiosarcoma in the United States: a population-based study of 4537 cases
Chao Zhang et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment
Jalal A. Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Sandra P. D'Angelo et al.
LANCET ONCOLOGY (2018)
Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma
Sanjay P. Bagaria et al.
FRONTIERS IN ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi et al.
LANCET ONCOLOGY (2017)
Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma
Gerardo Botti et al.
JOURNAL OF CANCER (2017)
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
Sandra P. D'Angelo et al.
HUMAN PATHOLOGY (2015)
Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial
Isabelle L. Ray-Coquard et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials
R. J. Young et al.
EUROPEAN JOURNAL OF CANCER (2014)
Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network
S. Stacchiotti et al.
ANNALS OF ONCOLOGY (2012)
Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas
Antoine Italiano et al.
CANCER (2012)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Angiosarcoma Clinical and Molecular Insights
Guy Lahat et al.
ANNALS OF SURGERY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study
Nicolas Penel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A 14-year retrospective review of angiosarcoma: Clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy
MG Fury et al.
CANCER JOURNAL (2005)